2 completed, 2 not yet recruiting, 1 recruiting, 1 unknown. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 2, Not yet recruiting 2, Recruiting 1, Unknown 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Untreated: new trials by email Literature Review of Untreated trials Research Report on Untreated
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma Epcoritamab, Observation - Randomized, Phase 2 | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 40 | 2027-02-12 | 2026-09-23 |
| A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease. Gemcitabine (1000 mg/m2), Nab-paclitaxel (Abraxane), NLM-001 - Untreated, Advanced Pancreatic Cancer | Phase 2 | Not yet recruiting | Nelum Corp | 40 | 2026-07-15 | 2026-05-13 |
| Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia Herombopag - Non Severe Aplastic Anemia, Untreated | Phase 2 | Completed | Institute of Hematology & Blood Diseases Hospital, China | 54 | 2022-12-01 | 2025-08-05 |
| Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement Lenalidomide, Rituximab, Etoposide - DLBCL, Untreated | Phase 1 / Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 81 | 2020-06-09 | 2020-06-16 |
| Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma Lenalidomide, R-CHOP, high-dose cytarabine (HIDAC) - Mantle Cell Lymphoma, Untreated | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 49 | 2015-12-14 | 2024-08-30 |
| Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) Lenalidomide and Rituximab - Chronic Lymphocytic Leukemia, CLL | Phase 2 | Unknown | Chronic Lymphocytic Leukemia Research Consortium | 80 | 2008-02-01 | 2010-09-10 |
Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1) · Neoplasms (1) · Pancreatic Neoplasms (1)
Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Lymphoma (2) · Lymphoma, Non-Hodgkin (2) · Chronic Disease (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Disease Attributes (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1)
Lenalidomide (3) · Rituximab (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Cyclophosphamide (1) · Cyclosporine (1) · Cytarabine (1) · Doxorubicin (1) · Etoposide (1) · Gemcitabine (1) · Observation (1) · Prednisone (1) · R-CHOP protocol (1) · Vincristine (1)
Chronic Lymphocytic Leukemia Research Consortium (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · Nelum Corp (1) · The First Affiliated Hospital with Nanjing Medical University (1)
United States (3) · China (2) · Spain (1)
Anita Kumar, MD (1) · Dai Chihara, MD (1) · Danelle F James, M.D. (1) · Thomas J Kipps, M.D., Ph.D (1) · Wei Xu, M.D., Ph.D (1)